NuScience Peptides Review (2026): Legit or Not?

The company trades at nusciencepeptides.com, plural, no hyphen. Two near-identical domains, nuscience-peptide.com and nusciencepeptide.com, appear in search indexes with copied marketing language. On September 23, 2026, neither resolved to a live server. Type the plural domain yourself rather than clicking a search ad.

The address question deserves a straight answer. The FDA warning letter is addressed to NuScience Peptides LLC at 20311 Chartwell Center Drive, Suite 212, Cornelius, North Carolina, to managers Joseph and Ratsamy DeRosa. The website footer and terms page say Albuquerque, New Mexico, and the terms name New Mexico courts. The listed phone number carries a 704 area code, which is Charlotte, NC.

Two vendor trackers report the LLC was registered January 3, 2024 in Mecklenburg County, NC. We could not access state records directly, so that date is reported, not verified. A vendor with a North Carolina registration, a North Carolina phone number and a New Mexico footer is not automatically dishonest, but the mismatch belongs on your list of questions to email before ordering.

On August 24, 2026, FDA's Center for Drug Evaluation and Research issued warning letter 733652 to NuScience Peptides LLC. It names nine products: GLP-2 Tirz (tirzepatide), GLP-1 Sema (semaglutide), GLP-3 RT (retatrutide), survodutide, mazdutide, PT-141, tesamorelin, a tesamorelin/ipamorelin blend and bacteriostatic water.

The allegation is the standard one from the 2026 FDA peptide crackdown: the products are unapproved new drugs under section 505(a), and the "research use only" disclaimer is contradicted by therapeutic claims on the product pages. FDA quotes the retatrutide listing describing "potential research applications in metabolic disorders, particularly obesity and type 2 diabetes." The company had 15 business days to respond.

The catalog reacted. By September 23, every URL for the named products returned a 404: the retatrutide page, both tirzepatide URLs, the semaglutide page, PT-141, tesamorelin, mazdutide and survodutide. The shop grid still displayed a Cagrilintide/GLP-1 SM blend at $74.99 to $129.99, but its product URL redirected to a removed page. Standalone cagrilintide at $121.99 for 5 mg stayed live.

If you came here for retatrutide, the practical answer is that NuScience no longer lists it. The retatrutide sourcing guide covers what a post-crackdown market looks like, and the legal framing sits in are peptides legal.

The live catalog runs about 40 products: repair peptides, growth-hormone secretagogues, bioregulators, NAD+, capsules and serums. Browsing requires an account and a 21+ confirmation at registration, though the terms page says 18.

Pricing lands mid-market, with no suspiciously cheap outliers. Most items showed a 20 to 50% "sale" badge, which is a permanent fixture at many research vendors rather than a real discount.

For the delisted GLP-1 products, the last tracked prices came from Finnrick's price-per-milligram record: retatrutide $17.80/mg, tirzepatide $15.00/mg, semaglutide $13.98/mg. A 10 mg retatrutide vial at that rate was roughly $178, inside the $150 to $250 band in the retatrutide cost guide. Run any basket through the peptide cost calculator and check the wider benchmarks in how much peptides cost.

NuScience states that "every batch has a COA published on our Lab Test Results page," with purity verified by HPLC and identity by mass spectrometry. That claim mostly holds. The lab-results page listed roughly 50 certificates on September 23, each tied to a product and lot number (TB-500 5 mg lot 00269, cagrilintide lot 05168, and so on), dated from 2024 into early 2026.

Two labs appear. Freedom Diagnostics is named on most current certificates. An older retatrutide COA still hosted on the site came from MZ Biolabs in Tucson, Arizona: lot 00176, tested January 31, 2025, HPLC-UV-MS purity 99.95%, measured mass 4728.49 Da against 4728.47 expected, and a measured quantity of 12.37 mg in a 10 mg vial.

Read that last number twice. The vial was overfilled by 24%. A COA that certifies identity and purity while documenting a quarter more peptide than the label is a passing certificate with a dosing problem inside it. One more oddity: the chromatogram filename embedded in that PDF references lot 00256 while the header states lot 00176. That may be a lab clerical slip, but it is the kind of detail a verification portal would catch, and NuScience has none.

No GLP-1 certificates remained on the lab page after the delisting. There is no ISO/IEC 17025 accreditation claim, no independent verify-by-code system like the Janoshik portal used by the vendor in our Prime Peptides review. One tracker reported in May 2026 that it found zero COAs on the site; we found about 50, so either the page was rebuilt or that audit missed it. Either way, match the lot on your vial to the certificate before you reconstitute anything, using the reconstitution calculator for the water volume.

Vendor COAs describe the batch the vendor chose to test. Independent retests describe what customers received. NuScience has more of the second kind than most vendors, and the results split sharply by product.

Finnrick, which grades on purity of 99.5% or higher and fill within 35% of label, logged 49 tests through August 26, 2026: 19 passed, 30 failed, a 38.8% pass rate and a 61% vendor rating, ranking #294 of 345 vendors.

TitrateLab, which aggregates 138 test records across 43 compounds, paints a more forgiving purity picture: mean purity 98.9%, median 99.6%, with 2 of 129 results below 90%. Its fill data is the alarming part. Of 71 dose measurements in the last 12 months, 14 were on target, 3 under label and 54 over. That matches the 12.37 mg retatrutide COA: this vendor's characteristic error is overfill, not underdosing.

So the honest read is this. Purity at NuScience is usually 99%+, which is why the purity-focused graders like Peptide Grades hand it an A overall. The fill accuracy is poor, which is why the stricter Finnrick standard fails it more often than not. Both statements are true at once.

Think of a vial as a bag of coffee beans sold by weight. If the bag says 250 g and holds 310 g, your usual scoop count brews stronger coffee than you planned. The literal version: a 10 mg label on a 12.37 mg vial means every unit you draw delivers 24% more peptide than your protocol assumes.

Scenario one, the silent overdose. You reconstitute a "10 mg" retatrutide vial with 2 mL, believing it is 5 mg/mL, and draw 40 units for a 2 mg dose. The vial actually held 12.37 mg, so the concentration is 6.19 mg/mL and you injected 2.47 mg. Over a titration schedule that error compounds, and GI side effects scale with dose. Fix: only use batches whose COA quantity sits within 10% of label, and recalculate concentration from the measured milligrams.

Scenario two, the purity miss. A batch tests at 93.68%, the low end of NuScience's retatrutide record. The missing 6.3% is unidentified material you are injecting subcutaneously. In a study of semaglutide bought from online sellers, purity ran 7.7% to 14.37% against a 99% label, content exceeded label by 28.56% to 38.69%, and endotoxin was found in every sample (Ashraf et al., J Med Internet Res, 2024, PMID 39509151). NuScience is nowhere near that floor, but the study shows why "99% claimed" is worthless without a batch number.

The fill problem is not new to gray-market peptides. Melanotan II vials bought from three online shops contained 4.32 to 8.84 mg against a 10 mg claim, with 4.1 to 5.9% unknown impurities (Breindahl et al., Drug Test Anal, 2015, PMID 24771717). Label and contents diverge in both directions across this market.

Vial-based GLP-1 dosing also removes the safety features of a manufactured pen. A poison-center case series documented two 10-fold semaglutide overdoses from patients dosing vials in units and milliliters instead of milligrams (Lambson et al., J Am Pharm Assoc, 2023, PMID 37392810). FAERS data show compounded GLP-1 products carry 2.35 times the odds of hospitalization and 19 times the odds of a contamination report versus manufactured versions (McCall et al., Expert Opin Drug Saf, 2026, PMID 40285721). FDA's own page on unapproved GLP-1 drugs counted 990 adverse event reports for compounded semaglutide and over 730 for compounded tirzepatide as of May 31, 2026. The peptide safety guide covers the handling basics that reduce the avoidable share of that risk.

Shipping is US only, including Alaska, Hawaii and Puerto Rico, with no international option. Orders placed before 12 PM Eastern on a business day ship the same day; the terms page allows 1 to 3 business days of processing. US orders over $200 ship free, and every shipment gets tracking. Domestic dispatch removes the customs-seizure risk that hits imported vials.

Payment methods are not listed on the terms page, and the account wall hides the checkout. One vendor directory reports PayPal is accepted; we could not confirm it. Ask before ordering, and prefer card or PayPal over crypto or Zelle so a chargeback remains possible.

Returns do not exist. The terms state the company "cannot accept returns," orders cannot be cancelled once shipped, and only damaged or incorrect items on arrival get a support email. Compare that to the "99% purity or your money back" guarantee in our NextGen Peptides review. At NuScience, the COA lot match is your only quality recourse, so do it before you break the seal, and store the vials as described in how to store peptides.

The public sentiment record is thin and positive. Peptide Critic lists a 5 out of 5 community rating from 6 reviews as of March 13, 2026, and its forum holds one user review from that date praising the vendor for replacing a package lost in transit and upgrading the shipping at no charge. That thread has zero replies.

A two-page ExcelMale thread titled "Ordered from NuScience Peptides" exists; the site blocked our access, and search snippets from it are favorable. No Reddit thread about NuScience surfaced in indexed search on September 23, 2026, which is unusual for a vendor selling GLP-1 peptides and means you cannot lean on r/peptides consensus here.

Trustpilot could not be verified. The review page sits behind a bot wall, one tracker cites a 4.7 score from 26 reviews, and two others state no Trustpilot profile exists. Treat any Trustpilot number for this vendor as unconfirmed.

Third-party grader scores diverge with their methods: Peptide Grades A (4.5/5) and Peptide Source Review 7.1/10 at #25 of 56 US vendors, with a 1.5/10 transparency sub-score for the unnamed-lab, no-portal setup. The same split appeared in our BioMax Peptides review: high purity averages, low verifiability.

The verdict: NuScience Peptides is a legitimate business in the sense that matters first. Orders ship, certificates exist, and the company answers the phone. It is not a vendor to trust blindly, because a third of its independently retested vials fail a strict standard, its characteristic defect is overfill, and it is 30 days out from an FDA warning letter that could reshape the catalog again.

If your compound is GHK-Cu, TB-500 or BPC-157 and you match the lot to a COA within 10% of label fill, the risk is ordinary for this market. If your compound is retatrutide, tirzepatide or semaglutide, NuScience no longer sells it, and the retatrutide sourcing guide and the Polaris Peptides review of the clinic model are the better starting points. For COA-first raw vendors, the Nexaph Peptides review applies the same checklist, and the Peptide Sciences alternatives guide maps what survived the crackdown.